|iCAD Announces FDA Clearance of Cervical Applicator; XenoPort May Be Beneficiary of Biogen Patents|
|By Staff and Wire Reports|
|Wednesday, 20 March 2013 18:59|
iCAD (Nasdaq: ICAD), a leading provider of advanced imaging and radiation therapy technologies for the detection and treatment of cancer, today announced that the company received U.S. Food and Drug Administration (FDA) clearance for its new cervical applicator for use with its Xoft® Axxent® Electronic Brachytherapy System® to deliver high dose rate brachytherapy for intracavitary treatment of cancer of the uterus, cervix, endometrium and vagina.
The regulatory clearance of Xoft's cervical applicator will help address an unmet need for improved cervical cancer treatment on a global level. According to the World Health Organization, cervical cancer is the second most common cancer in women worldwide, with about 500,000 new cases and 250,000 deaths each year.
“The addition of the cervical applicator broadens our gynecological product offering to provide treatment for patients with cervical or endometrial cancers. This regulatory clearance further demonstrates the advantages of the Xoft System platform which is also being used today in the treatment of certain breast and skin cancers,” said Ken Ferry, iCAD's CEO.
Xoft's cervical applicator is designed to treat locally advanced stage cervical cancer in combination with the Xoft System by delivering the prescribed radiation dose to the uterus, and cervix, endometrium and vagina with reduced radiation exposure to the surrounding healthy tissue. Brachytherapy is an important component in the curative management of cervical cancer and significantly improves survival.
The Xoft System is a mobile, isotope-free alternative to radionuclide-based high-dose radiation (HDR) brachytherapy and eliminates several logistical shortcomings associated with isotope, linear accelerator and external beam x-ray based radiation systems.
Xoft also recently received FDA clearance for an upgraded Xoft System controller capability that will support the cervical applicator and offer enhanced platform features.
Brian Abrahams, a Wells Fargo analyst, believes that Biogen (NASDAQ: BIIB) MS pill patents will be a positive boost for XenoPort (NASDAQ: XNPT).
Further patent applications could provide patent protection until 2032 for Biogen's BG-12, which should benefit XenoPort's '829 drug, an earlier stage derivative of BG-12, with added protection from generic competition.
BIIB is currently up 1.5 percent in pre-market trading, while XNPT is currently unchanged.
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biopharmaceutical company, will host an investor call to update investors on financial results for the quarter and the fiscal year ended December 31, 2012.
Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis centered around its patented therapeutic protein Mesencephalic Astrocyte Neurotrophic Factor (MANF), today announced that the Berlin-Bremen Stock Exchange (BBSE) has complied with the Company’s demand to cease the unauthorized listing of its common stock, and that as of today its shares are no longer traded on the BBSE.
Covidien plc (NYSE: COV) announced the results from today’s Annual General Meeting.
MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) would like to welcome a distinguished and accomplished new member to the Medifirst Solutions Advisory Board. Says CEO Bruce J. Schoengood, "I am very pleased to announce that Fred Valdez, MD has joined the company Advisory Board."
MediSwipe Inc. (OTCQB: MWIP), a patient security solutions and financial products company for the medicinal marijuana and health care industry, today commented on new bills and legislation to legalize medical cannabis dispensaries in Oregon and Nevada -- two states that have had MMJ laws on the books for years but do not technically allow storefront centers.
MYOS Corporation (OTCBB: MYOS), a company focused on the discovery, development and commercialization of muscle health nutritional supplements, functional foods, and therapeutic products, today announced results from a recently completed clinical study designed to better understand the effect of its initial oral product, MYO-T12®, on myostatin levels in healthy male subjects.
NanoViricides, Inc. (OTC BB: NNVC) announced its President, Dr. Anil Diwan, has been invited to present a seminar at the University of California, Los Angeles.
Obagi Medical Products, Inc (NASDAQ: OMPI) today announced that it entered into a definitive merger agreement with Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) (“Valeant”) under which Valeant will acquire all of the outstanding common stock of Obagi for $19.75 per share in cash.
Prospect Capital Corporation (NASDAQ: PSEC) ("Prospect") announced today that Prospect has provided $47 million of senior secured first-lien debt financing to support the acquisition of Atlantis Health Care Group (Puerto Rico), Inc. ("Atlantis") by ICV Partners, a leading investment firm focused on lower middle-market companies.
RTI Biologics Inc. (RTI) (Nasdaq: RTIX), a leading provider of orthopedic and other biologic implants, is pleased to announce the results of a recent randomized prospective clinical study of BioCleanse®-processed bone-patellar tendon-bone (BTB) allografts used in anterior cruciate ligament (ACL) reconstruction surgery.
Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that it has entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Obagi Medical Products, Inc. (NASDAQ: OMPI) for $19.75 per share in cash, which represents a 28% premium to Obagi's closing share price on March 19, 2013, the last trading day prior to announcement.